RedHill Biopharma Announces U.S. Commercialization Agreement for FDAApproved...
RedHill was granted the exclusive rights to promote Esomeprazole Strontium DelayedRelease DR Capsules to gastroenterologists in certain U.S. territoriesEsomeprazole Strontium DR Capsules 49.3 mg is an...
View ArticleInadequate Tcell development linked to autoimmune diseases
As part of their ongoing fundamental research program scientists at the Monash Biomedicine Discovery Institute have built on previous research which had determined that the enzyme protein tyrosine...
View ArticleLab tests show molecule appears to spur cell death in tumours
A druglike molecule developed by Duke Health researchers appears to intercede in an inflammatory response that is at the centre of a variety of diseases including some cancers rheumatoid arthritis and...
View ArticleIncontinence and Ostomy Care Global Market Forecast to 2023 Report Updated...
Incontinence and ostomy care consist of products that are essential for patients with incontinence and stoma. With the projected rise in aged population and awareness about such conditions the market...
View ArticleChemoCentryx Inc CCXI Financial and Strategic SWOT Analysis Review Report...
SummaryChemoCentryx Inc ChemoCentryx is a biopharmaceutical company that discovers develops and commercializes orallyadministered therapeutics for the treatment of cancer autoimmune diseases and...
View ArticleTiGenix NV TIG Financial and Strategic SWOT Analysis Review Report Updated...
SummaryTiGenix NV TiGenix is a biopharmaceutical company that develops and commercializes novel therapeutics. Its product portfolio includes AlloCSC01 AlloCSC02 Cx611 and Cx601. The company develops...
View ArticleCrohn's Disease Regional Enteritis Global Clinical Trials Review H2 2017...
Crohn's Disease Regional Enteritis Global Clinical Trials Review H2 2017SummaryGlobalData's clinical trial report Crohn's Disease Regional Enteritis Global Clinical Trials Review H2 2017" provides an...
View ArticleOncobiologics Inc ONSIU Financial and Strategic SWOT Analysis Review Report...
SummaryOncobiologics Inc Oncobiologics is a biopharmaceutical company that develops and markets biosimilar therapeutics. The company's product pipeline comprises ONS3010 and ONS1045. It uses...
View ArticleImmune Pharmaceuticals Inc IMNP Financial and Strategic SWOT Analysis Review...
SummaryImmune Pharmaceuticals Inc Immune Pharma formerly EpiCept Corporation is a pharmaceutical company that develops antibody therapeutics for the treatment of patients with inflammatory diseases and...
View ArticleArena Pharmaceuticals to Present Additional PreClinical Data on Ralinepag for...
SAN DIEGO Aug. 22 2017 PRNewswire Arena Pharmaceuticals Inc. NASDAQ ARNA will present additional detailed preclinical pharmacology and pharmacokinetic data on ralinepag APD811 the Company's...
View ArticleTiGenix NV TIG Medical Equipment Deals and Alliances Profile. Report Updated...
SummaryTiGenix NV TiGenix is a biopharmaceutical company that develops and commercializes novel therapeutics. Its product portfolio includes AlloCSC01 AlloCSC02 Cx611 and Cx601. The company develops...
View ArticleLiquid nutrition may benefit children with Crohn's disease
Wiley An analysis of published studies indicates that exclusive enteral nutrition EEN when individuals receive only liquid nutrition may be an effective treatment for children with Crohn's disease.
View ArticleMycenax Biotech Inc 4726 Financial and Strategic SWOT Analysis Review Report...
SummaryMycenax Biotech Inc Mycenax is a biopharmaceutical company that develops and manufactures pharmaceutical formulations. The company's pipeline portfolio encompasses investigational candidates...
View ArticleIBM Your Computer Can Help Scientists Study Connection Between Body Bacteria...
ARMONK N.Y. Aug. 23 2017 PRNewswire The general public's help is being enlisted in what's thought to be the biggest study of the human microbiomethe bacteria that live in and on the human body and are...
View ArticleCVS Health's Accordant Earns NCQA Disease Management Accreditation for 18...
WOONSOCKET R.I. Aug. 23 2017 PRNewswire Accordant a CVS Health NYSE CVS company and an integral part of CVS Specialty announced today that it has received NCQA Patient and Practitioner Oriented Disease...
View ArticleTranscriptional risk scores link GWAS to eQTLs and predict complications in...
Greg Gibson and colleagues integrate summarylevel GWAS and eQTL data with RNAseq data from a cohort of pediatric Crohn's disease and report transcriptional risk scores that identify patients who will...
View ArticleProtagonist Therapeutics Announces Closing of Janssen License and...
NEWARK Calif. Aug. 24 2017 PRNewswire Protagonist Therapeutics Inc. Nasdaq PTGX today announced it has closed the worldwide license and collaboration transaction for PTG200 with Janssen Biotech Inc....
View ArticleSamsung Bioepis First to Obtain European Commission Approval for a Third...
Samsung Bioepis Co. Ltd. today announced the European Commissions EC approval of Imraldi a biosimilar referencing Humira 1 adalimumab for the treatment of rheumatoid arthritis juvenile idiopathic...
View ArticleIMRALDI Biogens Adalimumab Biosimilar Referencing Humira is Approved in the...
Biogen becomes the first company with approved biosimilars for the three most prescribed antiTNF biologic treatments in Europe. The European Commission EC granted a marketing authorization for IMRALDIÂ...
View ArticleBiosimilar to Humira approved in Europe
Samsung Bioepis Co. Ltd. announced the European Commission has approved Imraldi a biosimilar to Humira for the treatment of rheumatoid arthritis juvenile idiopathic arthritis axial spondyloarthritis...
View Article